The UK government has confirmed indefinite recognition of eligible CE marked medical devices in Great Britain, allowing manufacturers to continue placing products approved under applicable European rules on the market without obtaining a separate UKCA conformity assessment solely for access to Great Britain. The decision was confirmed by the Medicines and Healthcare products Regulatory Agency on 21 October.
The policy covers eligible medical devices and in vitro diagnostic devices, including products used in surgery, patient monitoring and laboratory testing. Manufacturers may continue to use the domestic UKCA conformity route, but eligible products already approved through European arrangements will not require a second UKCA assessment simply to reach the Great Britain market. The detailed application depends on the device and its regulatory pathway.
More than 90% of medical devices registered for use in Great Britain currently carry CE marking, according to the regulator. The figure illustrates how extensively the domestic supply of diagnostics, hospital equipment and patient devices relies on products assessed for the European market. The decision therefore affects established manufacturing and distribution routes rather than introducing an entirely new product category.
Conformity assessment involves classifying a medical device by risk, documenting its intended use, establishing evidence of safety and performance, and maintaining production controls that preserve the approved design. Devices classified at higher risk generally require scrutiny by an external assessment body; different routes apply to some devices and diagnostics classified at lower risk. CE marking signals completion of an applicable European process, but the supporting technical documentation and surveillance obligations remain central.
A manufacturer selling the same device across Europe and Great Britain may avoid repeating an assessment already completed under qualifying EU rules. The decision does not waive the conditions attached to the CE certification or authorise every product carrying a CE logo regardless of classification. Manufacturers, importers and distributors still need to meet registration, traceability, vigilance and applicable requirements for placing devices on the market.
The decision follows a public consultation conducted from 16 February to 10 April 2026 that received more than 1,000 responses from patients, health services, industry and others. The consultation examined the treatment of devices certified under earlier EU medical device directives, indefinite recognition of EU MDR and EU IVDR routes, and a proposed reliance process where a device has a higher risk classification in Great Britain than in the EU.
Products assessed under the newer EU Medical Device Regulation and In Vitro Diagnostic Regulation are subject to different rules from those certified under older directives. The MHRA’s decision establishes the long-term policy direction; individual certificate validity, transition arrangements and any reliance route depend on the detailed rules in force as implementation progresses. Existing dated guidance should not be read as proof that every old certificate has become valid indefinitely.
The decision applies to Great Britain. Northern Ireland operates under a separate regulatory position linked to the relevant European medical device framework, and the new Great Britain recognition announcement should not be taken as replacing the rules that apply there. Multisite manufacturers and distributors need to maintain the market distinctions in product labelling, registration and supply documentation.
The MHRA is separately modernising the UKCA pathway through proposed changes to pre-market requirements. It also intends to seek legislative powers for a future medical device licensing framework that can respond to technologies such as software-based and AI-enabled medical devices. Indefinite CE recognition is not a substitute for those reforms, which require their own legal and technical provisions.
Safety monitoring after products have been supplied remains part of the regulatory regime. The MHRA has reinforced requirements covering post-market surveillance and reporting, and it monitors adverse incidents through channels that include the Yellow Card scheme. Recognition of another conformity system therefore operates alongside domestic surveillance, with the regulator retaining the ability to investigate safety issues and take action where required.
The continued recognition of qualifying CE assessments influences how manufacturers manage technical files, quality systems and approved product changes. Changes to software, materials, intended use or a manufacturing process can trigger reassessment of conformity even where a device has an established route to market. Accurate product identification, instructions, supplier controls and distribution records therefore remain part of regulatory compliance in Great Britain.
Component manufacturers supplying medical electronics, precision instruments, mouldings and sterile assemblies operate within those controls through their customers’ quality systems. Material substitutions and component design revisions can affect the evidence supporting a finished device’s approval, including traceability and performance verification. Avoiding duplicate national conformity assessments may simplify market access for the finished device, but does not remove the obligation to document and validate supplier changes.
The government plans further engagement with patients, clinicians and industry as recognition is implemented. The MHRA will continue post-market surveillance, incident reporting and action on defective devices alongside the UKCA route. Manufacturers will still need to check the final rules for their specific European certificate and the regulatory requirements applying separately in Northern Ireland.
